These in vitro findings suggest a potential preclinical rationale for combining progesterone with PARP inhibitors in BRCA-wild-type ovarian cancer; in vivo validation and dosing studies are needed before clinical consideration. The gene discussed is PARP1; the disease is ovarian cancer.